136 related articles for article (PubMed ID: 22236455)
1. Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin.
Apisarnthanarak A; Mundy LM
Int J Antimicrob Agents; 2012 Mar; 39(3):271-2. PubMed ID: 22236455
[No Abstract] [Full Text] [Related]
2. Use of high-dose 4-hour infusion of doripenem, in combination with fosfomycin, for treatment of carbapenem-resistant Pseudomonas aeruginosa pneumonia.
Apisarnthanarak A; Mundy LM
Clin Infect Dis; 2010 Dec; 51(11):1352-4. PubMed ID: 21050114
[No Abstract] [Full Text] [Related]
3. In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa.
Di X; Wang R; Liu B; Zhang X; Ni W; Wang J; Liang B; Cai Y; Liu Y
J Antibiot (Tokyo); 2015 Sep; 68(9):551-5. PubMed ID: 25805069
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.
Chastre J; Wunderink R; Prokocimer P; Lee M; Kaniga K; Friedland I
Crit Care Med; 2008 Apr; 36(4):1089-96. PubMed ID: 18379232
[TBL] [Abstract][Full Text] [Related]
5. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model.
Lora-Tamayo J; Murillo O; Bergen PJ; Nation RL; Poudyal A; Luo X; Yu HY; Ariza J; Li J
J Antimicrob Chemother; 2014 Sep; 69(9):2434-42. PubMed ID: 24833752
[TBL] [Abstract][Full Text] [Related]
6. Current therapies for pseudomonas aeruginosa.
Giamarellou H; Kanellakopoulou K
Crit Care Clin; 2008 Apr; 24(2):261-78, viii. PubMed ID: 18361945
[TBL] [Abstract][Full Text] [Related]
7. Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
Song JY; Lee J; Heo JY; Noh JY; Kim WJ; Cheong HJ; Hwang IS
Int J Antimicrob Agents; 2008 Sep; 32(3):281-4. PubMed ID: 18650070
[No Abstract] [Full Text] [Related]
8. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
Eagye KJ; Banevicius MA; Nicolau DP
Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases.
Santimaleeworagun W; Wongpoowarak P; Chayakul P; Pattharachayakul S; Tansakul P; Garey KW
Southeast Asian J Trop Med Public Health; 2011 Jul; 42(4):890-900. PubMed ID: 22299471
[TBL] [Abstract][Full Text] [Related]
10. Safety of intravenous infusion of doripenem.
Redman R; File TM
Clin Infect Dis; 2009 Aug; 49 Suppl 1():S28-35. PubMed ID: 19619019
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa.
Aoki N; Tateda K; Kikuchi Y; Kimura S; Miyazaki C; Ishii Y; Tanabe Y; Gejyo F; Yamaguchi K
J Antimicrob Chemother; 2009 Mar; 63(3):534-42. PubMed ID: 19147523
[TBL] [Abstract][Full Text] [Related]
12. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation.
Asuphon O; Montakantikul P; Houngsaitong J; Kiratisin P; Sonthisombat P
Int J Infect Dis; 2016 Sep; 50():23-9. PubMed ID: 27418581
[TBL] [Abstract][Full Text] [Related]
13. Doripenem: a new carbapenem in the treatment of nosocomial infection.
Mandell L
Clin Infect Dis; 2009 Aug; 49 Suppl 1():S1-3. PubMed ID: 19619016
[TBL] [Abstract][Full Text] [Related]
14. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.
Ly NS; Bulitta JB; Rao GG; Landersdorfer CB; Holden PN; Forrest A; Bergen PJ; Nation RL; Li J; Tsuji BT
J Antimicrob Chemother; 2015 May; 70(5):1434-42. PubMed ID: 25712313
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of fosfomycin and carbapenems against carbapenem-resistant Pseudomonas aeruginosa clinical isolates.
Kunakonvichaya B; Thirapanmethee K; Khuntayaporn P; Montakantikul P; Chomnawang MT
Int J Antimicrob Agents; 2015 May; 45(5):556-7. PubMed ID: 25724628
[No Abstract] [Full Text] [Related]
16. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
Mushtaq S; Ge Y; Livermore DM
Antimicrob Agents Chemother; 2004 Aug; 48(8):3086-92. PubMed ID: 15273124
[TBL] [Abstract][Full Text] [Related]
17. [Importance of appropriate carbapenem use to reduce carbapenem--resistant Pseudomonas aeruginosa].
Furukawa K
Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():258-64. PubMed ID: 17455627
[No Abstract] [Full Text] [Related]
18. In vitro activity of doripenem plus fosfomycin against drug-resistant clinical blood isolates.
Lingscheid T; Tobudic S; Poeppl W; Mitteregger D; Burgmann H
Pharmacology; 2013; 91(3-4):214-8. PubMed ID: 23548688
[TBL] [Abstract][Full Text] [Related]
19. Options for treating carbapenem-resistant Enterobacteriaceae.
Rafailidis PI; Falagas ME
Curr Opin Infect Dis; 2014 Dec; 27(6):479-83. PubMed ID: 25259809
[TBL] [Abstract][Full Text] [Related]
20. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
